Your browser doesn't support javascript.
loading
Urinary MicroRNA Sensing Using Electrochemical Biosensor to Evaluate Colorectal Cancer Progression.
Pang, Sow-Neng; Lin, Yu-Lun; Chiou, Yueh-Er; Leung, Wai-Hung; Weng, Wen-Hui.
Afiliação
  • Pang SN; Department of General Medicine, Mater Misericordiae University Hospital, D07 R2WY Dublin, Ireland.
  • Lin YL; Department of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei City 106, Taiwan.
  • Chiou YE; Department of Nursing, College of Medicine, Fu Jen Catholic University, New Taipei City 242, Taiwan.
  • Leung WH; Division of Colorectal Surgery, Department of Surgery, Mackay Memorial Hospital, Taipei City 104, Taiwan.
  • Weng WH; Department of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei City 106, Taiwan.
Biomedicines ; 10(6)2022 Jun 17.
Article em En | MEDLINE | ID: mdl-35740455
ABSTRACT
Research in cancer diagnostics has recently established its footing and significance in the biosensor sphere, emphasizing the idea of a unique probe design used as a sensor and actuator, to identify the presence of protein, DNA, RNA, or miRNA. The fluorescein isothiocyanate (FITC) probe and biotinylated probe are designed for a two-pronged approach to the detection of the urinary miR-21 and miR-141, both of which have demonstrated significance in the development and progression of colorectal cancer, a leading cause of mortality and morbidity. The remainder of the apparatus is composed of a modified screen-printed carbon electrode (SPCE), to which the probes adhere, that transduces signals via the redox reaction between H2O2 and HRP, measured with chronoamperometry and cyclic voltammetry. The precise nature of our ultra-non-invasive biosensor makes for a highly sensitive and practical cancer detector, concluded by the significance when establishing disease presence (miR-21 p-value = 0.0176, miR-141 p-value = 0.0032), disease follow-up (miR-21 p-value = 0.00154, miR141 p-value < 0.0005), and even disease severity. This article hopes to emphasize the potential of an additional clinical tool for the management of colorectal cancer.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article